Takeshi Kato

11PUBLICATIONS
135CO-AUTHORS
Predictive and prognostic markersCancer diagnosisMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Aug 20, 2026
Clinical significance of WES-defined ERBB2 amplification in resectable colorectal cancer.

|Jul 01, 2026
Cell-Free DNA Analysis With Clinicopathologic Factors for Early Detection and Refining Lymph Node Metastasis Risk in T1 Colorectal Cancer: Results From the COSMOS-CRC Study.

|May 09, 2025
Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study.

Kentaro Sawada, Riu Yamashita, Shunsuke A Sakai

|Nov 08, 2024
A Tumor-Naïve ctDNA Assay Detects Minimal Residual Disease in Resected Stage II or III Colorectal Cancer and Predicts Recurrence: Subset Analysis from the GALAXY Study in CIRCULATE-Japan.

Yoshiaki Nakamura, Kristiyana Kaneva, Christine Lo

|Aug 20, 2024
Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody-Based Therapy in ERBB2-Amplified Metastatic Colorectal Cancer.

Naoko Iida, Mitsuho Imai, Wataru Okamoto

|Feb 08, 2024
Outcomes of Metastatic and Unresectable Small Bowel Adenocarcinoma in Japan According to the Treatment Strategy: A Nationwide Observational Study.

Yoshitaka Nishikawa, Takahiro Horimatsu, Shiro Oka

Pageof 2

Frequent Collaborators

8 joint publications

Hideaki Bando

7 joint publications

Takayuki Yoshino

7 joint publications

Eiji Oki

6 joint publications

Yoshiaki Nakamura